NCT00110994 2015-06-08
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 2 Completed
Clinical Trials
5 trialsNCT00111007 2014-10-31
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 3 Completed
NCT00492297 2014-10-31
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Bayer
Phase 2 Completed
NCT00827177 2014-01-24
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00498836 2013-09-12
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
Clavis Pharma
Phase 2 Completed